The U.S. Food and Drug Administration (FDA) granted a supplemental application approval for Filspari (sparsentan) on April 13, 2026. This approval, designated as NDA 216403 S-6, specifically pertains to the drug's efficacy.
Background
Filspari (sparsentan) is a medication developed by the sponsor TRAVERE. This supplemental approval from the FDA addresses the efficacy aspect of the drug, building upon its existing regulatory profile.
What this means
A supplemental approval for efficacy signifies that the FDA has reviewed additional data supporting the effectiveness of Filspari (sparsentan). This type of approval can lead to updated prescribing information, a refinement of its approved use, or a broader understanding of its benefits for patients. For clinicians, this represents a further validation of the drug's ability to achieve its intended therapeutic effects, which can inform treatment decisions. Researchers may find this updated information valuable for understanding the evolving data landscape for sparsentan, while patient advocates can use it to better understand the drug's established benefits and potential applications.
Source
The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA) on April 13, 2026. The details of this supplemental application (NDA 216403 S-6) are publicly available on accessdata.fda.gov.